XBIO
NASDAQXenetic Biosciences Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$3.40+0.88 (+34.92%)
2026-03-022026-06-03
News · 26 weeks21+25%
2025-12-072026-05-31
Mix1290d
- SEC Filings6(50%)
- Market4(33%)
- Insider1(8%)
- Other1(8%)
Latest news
25 items- NEWSXenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and SurvivalNew preclinical and translational findings position DNase I as a potentially transformative adjunct therapy for CAR-T treatment in aggressive B cell malignanciesData highlight potential of DNase I to improve CAR-T cell expansion, reduce exhaustion and enhance tumor control across hematologic cancer modelsFindings support continued clinical development of DNase I as a combinatorial strategy to augment CAR-T cell therapies in difficult-to-treat cancersData to be presented today as a poster presentation at the ASCO 2026 annual meeting FRAMINGHAM, MA / ACCESS Newswire / June 1, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on adv
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Xenetic Biosciences Inc.SCHEDULE 13G/A - Xenetic Biosciences, Inc. (0001534525) (Subject)
- SECXenetic Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Xenetic Biosciences, Inc. (0001534525) (Filer)
- NEWSXenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology PlatformAdvancements across investigator-initiated studies, translational research and manufacturing activities supporting future clinical developmentStrengthened financial profile with continued royalty revenue growthEnded first quarter 2026 with approximately $7.3 million in cash while continuing evaluation of strategic alternatives to maximize shareholder value FRAMINGHAM, MA / ACCESS Newswire / May 13, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the quarter ended March 31, 2026 and provided a corp
- SECSEC Form 10-Q filed by Xenetic Biosciences Inc.10-Q - Xenetic Biosciences, Inc. (0001534525) (Filer)
- SECAmendment: SEC Form 10-K/A filed by Xenetic Biosciences Inc.10-K/A - Xenetic Biosciences, Inc. (0001534525) (Filer)
- SECXenetic Biosciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Xenetic Biosciences, Inc. (0001534525) (Filer)
- INSIDERInterim CEO and CFO Parslow James F was granted 100,000 shares (SEC Form 4)4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)
- NEWSXenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual MeetingFRAMINGHAM, MA / ACCESS Newswire / April 22, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its abstract has been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 - June 2, 2026, in Chicago, IL. The accepted abstract, titled "Targeting cfDNA and NETs with DNase I to augment CAR T cell function and antitumor efficacy," highlights preclinical research supporting Xenetic's DNase-based therapeutic approach designed to enhance CAR T-cell activit
- SECXenetic Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Xenetic Biosciences, Inc. (0001534525) (Filer)
- NEWSXenetic Biosciences, Inc. Reports Full Year 2025 Financial ResultsEncouraging preclinical and translational data supporting DNase-based approaches to target NETs in difficult-to-treat cancersStrategic focus on investigator-initiated exploratory studies and institutional collaborationsContinued progress toward IND-enabling activities for DNase I programEnded the year with $7.9 million of cash to fund operationsFRAMINGHAM, MA / ACCESS Newswire / March 13, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the year ended December 31, 2025.Recent HighlightsExpanded and
- SECSEC Form 10-K filed by Xenetic Biosciences Inc.10-K - Xenetic Biosciences, Inc. (0001534525) (Filer)
- SECSEC Form SCHEDULE 13G filed by Xenetic Biosciences Inc.SCHEDULE 13G - Xenetic Biosciences, Inc. (0001534525) (Subject)
- SECXenetic Biosciences Inc. filed SEC Form 8-K: Other Events8-K - Xenetic Biosciences, Inc. (0001534525) (Filer)
- INSIDERSEC Form 4 filed by Director Borisenko Grigory G.4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)
- INSIDERSEC Form 4 filed by Director Dastoor Firdaus J.4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)
- INSIDERSEC Form 4 filed by Director Kornberg Roger D.4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)
- INSIDERSEC Form 4 filed by Director Vinogradov Alexey Andreevich4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)
- SECSEC Form DEFA14A filed by Xenetic Biosciences Inc.DEFA14A - Xenetic Biosciences, Inc. (0001534525) (Filer)
- SECXenetic Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Xenetic Biosciences, Inc. (0001534525) (Filer)
- NEWSXenetic Biosciences, Inc. Announces Adjournment of 2025 Annual MeetingAdjourns 2025 Annual Meeting of StockholdersUrges Stockholders Who Have Not Voted To Get Votes In FRAMINGHAM, MA / ACCESS Newswire / December 11, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its 2025 Annual Meeting of Stockholders (the "Annual Meeting") was convened and adjourned without any business conducted due to lack of the required quorum.A quorum is necessary to hold the Annual Meeting. There were fewer than a majority of the outstanding shares entitled to vote present, either in person or by proxy, at the
- NEWSXenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase PlatformFRAMINGHAM, MA / ACCESS Newswire / November 19, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced it has executed a 4-month extension of its collaboration with The Scripps Research Institute ("Scripps Research") and the lab of Dr. Alexey Stepanov, Institute Investigator at Scripps Research effective November 1, 2025, to advance the development of the Company's research and development program evaluating the combination of systemic DNase I and CAR T-cell therapies.Xenetic's systemic DNase I candidate, XBIO-015, is currently
- SECXenetic Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Xenetic Biosciences, Inc. (0001534525) (Filer)
- NEWSXenetic Biosciences, Inc. Reports Third Quarter 2025 Financial ResultsContinued execution on collaborations and exploratory investigator-initiated studies with institutional partnersSecured net proceeds of approximately $3.9 million from October 2025 offering FRAMINGHAM, MA / ACCESS Newswire / November 13, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the third quarter 2025. "We are steadily building the foundation for potentially transformative progress in the oncology treatment paradigm as we advance our systemic DNase I program in combination with established
- SECSEC Form 10-Q filed by Xenetic Biosciences Inc.10-Q - Xenetic Biosciences, Inc. (0001534525) (Filer)
XBIO FAQ
5 questionsWhat does Xenetic Biosciences Inc. do?
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The company is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and...Where does XBIO stock trade?
Xenetic Biosciences Inc. (XBIO) is listed on NASDAQ.What sector and industry is XBIO in?
Xenetic Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to XBIO?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare XBIO side-by-side with any of them on Quantisnow.How can I track XBIO on Quantisnow?
Quantisnow aggregates Xenetic Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow XBIO to receive live email and push alerts on every new disclosure.